Updated
Updated · Yahoo Finance · Aug 20
Natera Rallies 37% in 2026, Becomes Duquesne's $865 Million Top Holding
Updated
Updated · Yahoo Finance · Aug 20

Natera Rallies 37% in 2026, Becomes Duquesne's $865 Million Top Holding

2 articles · Updated · Yahoo Finance · Aug 20

Summary

  • $865 million of Duquesne Family Office's portfolio was in Natera at June 30, making the diagnostics company Stanley Druckenmiller's largest holding at 16.6% of assets.
  • A 37% share gain this year drove much of that rise after Natera won Japan approval in June for Signatera colorectal cancer testing and then posted strong second-quarter results.
  • Q2 revenue jumped 37.7% to $752.8 million from $546.6 million, gross margin improved by more than 100 basis points, and management lifted full-year revenue guidance to $2.91 billion from $2.85 billion.
  • The rally has far outpaced the S&P 500's 13.9% gain, leaving investors weighing whether Natera's dominant MRD testing position still supports further upside after valuation concerns had earlier capped the stock.

Insights

With Natera up 37% this year, does its recent regulatory breakthrough in Japan justify jumping in, or is the upside fully priced?
Could Natera's rapidly growing genomic dataset make it a hidden tech play rather than just a traditional healthcare diagnostics company?
Why did a legendary macro investor just bet $865 million on a single cancer testing stock trading at a massive premium?